Clinical Trials Directory

Trials / Conditions / Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

24 registered clinical trials studyying Relapsed and/or Refractory Multiple Myeloma — 2 currently recruiting.

StatusTrialSponsorPhase
TerminatedON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT06351644
Adriana RossiPhase 1 / Phase 2
RecruitingA Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06153251
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyPhase 1
RecruitingOriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
NCT06182696
OriCell Therapeutics Co., Ltd.Phase 1 / Phase 2
UnknownAssess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukem
NCT05893693
Aibin Liang，MD，Ph.D.N/A
UnknownEvaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multipl
NCT05719701
Beijing InnoCare Pharma Tech Co., Ltd.Phase 1 / Phase 2
UnknownThis is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in
NCT05486975
The First Affiliated Hospital of Soochow UniversityEARLY_Phase 1
UnknownRetrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory
NCT05297240
PETHEMA Foundation—
UnknownA Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myelo
NCT05066022
The First Affiliated Hospital of Soochow UniversityN/A
WithdrawnA Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therap
NCT04392648
Teva Branded Pharmaceutical Products R&D LLCPhase 1
TerminatedA Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma
NCT04017130
Molecular Templates, Inc.Phase 1
UnknownQuality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multipl
NCT03903406
Multinational Center for Quality of Life Research, Russia—
TerminatedAssessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT03836053
AmgenPhase 1
Active Not RecruitingMulti-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
NCT03715478
Canadian Myeloma Research GroupPhase 1 / Phase 2
CompletedA Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and De
NCT03433001
Takeda—
CompletedA Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in
NCT03416374
TakedaPhase 4
UnknownCarfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03140943
National University Hospital, SingaporePhase 2
CompletedA Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
NCT03170882
Millennium Pharmaceuticals, Inc.Phase 2
CompletedA Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Re
NCT02917941
TakedaPhase 2
CompletedA Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
NCT02831686
Memorial Sloan Kettering Cancer CenterPhase 1
CompletedThe Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Tr
NCT03242460
Kosin University Gospel HospitalPhase 2
TerminatedA Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
NCT04272775
TakedaPhase 1
CompletedSafety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Mul
NCT01632150
Bristol-Myers SquibbPhase 2
CompletedStudy To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma
NCT00882063
Piramal Enterprises LimitedPhase 1 / Phase 2
Approved For MarketingExpanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma
NCT04534322
Oncopeptides AB—